Wedbush Predicts Reduced Earnings for Travere Therapeutics

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at Wedbush lowered their Q4 2025 earnings per share (EPS) estimates for Travere Therapeutics in a research report issued on Monday, February 24th. Wedbush analyst L. Chico now expects that the company will post earnings per share of $0.12 for the quarter, down from their prior forecast of $0.15. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ FY2026 earnings at $1.35 EPS, FY2027 earnings at $3.23 EPS and FY2028 earnings at $3.75 EPS.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The firm had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million.

Other analysts have also issued research reports about the company. Piper Sandler upped their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. HC Wainwright increased their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, January 15th. Barclays lifted their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Travere Therapeutics in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.62.

Travere Therapeutics Stock Up 1.8 %

Shares of TVTX stock opened at $21.03 on Wednesday. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $25.29. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -5.13 and a beta of 0.72. The firm’s 50-day moving average is $19.90 and its 200-day moving average is $16.89.

Insider Buying and Selling

In related news, CAO Sandra Calvin sold 54,244 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the sale, the chief accounting officer now directly owns 54,410 shares in the company, valued at approximately $1,360,250. The trade was a 49.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP William E. Rote sold 5,200 shares of the firm’s stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total value of $122,356.00. Following the transaction, the senior vice president now owns 98,519 shares in the company, valued at approximately $2,318,152.07. This trade represents a 5.01 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 206,335 shares of company stock valued at $4,453,012. 4.06% of the stock is owned by company insiders.

Institutional Trading of Travere Therapeutics

A number of institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in shares of Travere Therapeutics in the fourth quarter worth $31,000. Sterling Capital Management LLC grew its stake in Travere Therapeutics by 859.8% during the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock worth $41,000 after buying an additional 2,115 shares in the last quarter. R Squared Ltd bought a new position in Travere Therapeutics in the 4th quarter valued at about $53,000. Gen Wealth Partners Inc acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at approximately $73,000. Finally, Quarry LP bought a new stake in shares of Travere Therapeutics during the 3rd quarter worth approximately $105,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.